ICI 182,780 (Faslodex) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00417430 (ClinicalTrials.gov) | September 2004 | 28/12/2006 | Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies | Phase II Study of Efficacy of ICI 182,780 (Faslodex) in the Treatment of Systemic Lupus Erythematosus: Clinical, Serologic, Molecular | Systemic Lupus Erythematosus | Drug: ICI 182,780 (Faslodex) | The Center for Rheumatic Disease, Allergy, & Immunology | AstraZeneca | Completed | 16 Years | 50 Years | Female | 20 | Phase 2 | United States |